EMA Says Study Found Patients Who Received Blenrep Did Not Live Longer Without Disease Getting Worse Than Those Received Pomalidomide Plus Dexamethasone
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has found that patients who received Blenrep did not live longer without their disease getting worse than those who received Pomalidomide plus Dexamethasone. GlaxoSmithKline (GSK) is the manufacturer of Blenrep.
September 15, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The EMA's findings may negatively impact GSK as it suggests that their drug, Blenrep, does not provide significant benefits over existing treatments.
The EMA's findings suggest that Blenrep, a drug manufactured by GSK, does not provide significant benefits over Pomalidomide plus Dexamethasone. This could potentially affect the sales and market share of Blenrep, thereby negatively impacting GSK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100